RTP Mobile Logo
Lunch with the Investigators: Acute Myeloid Leukemia and Myelodysplastic Syndromes (Webinar Video Proceedings)
Released June 2022

Featuring perspectives from Drs Courtney DiNardo, Michael Savona and Eunice Wang. Published June 20, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.


    • Evaluate the importance of patient age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for various presentations of acute myeloid leukemia (AML).
    • Appreciate the FDA approval of venetoclax with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are 75 years old or older or not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
    • Reflect on published research with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
    • Understand the mechanisms of action of, available data with and current and emerging role for available IDH1/2 inhibitors for newly diagnosed or relapsed/refractory AML with an IDH1 or IDH2 mutation.
    • Assess the FDA-approved indication for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
    • Formulate a treatment algorithm for lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
    • Develop an understanding of the biologic rationale for and available data with emerging novel combination regimens for higher-risk myelodysplastic syndromes in order to prepare for their potential availability in routine practice.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component and short post-test, enables the participant to earn up 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO22AMLMDS/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Courtney D DiNardo, MD, MSCE
    Associate Professor, Department of Leukemia
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, CleaveTherapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs.

    Michael R Savona, MD
    Section Head, Hematology, Cellular Therapy and Stem Cell Transplantation
    Beverly and George Rawlings Directorship in Hematology Research
    Professor of Medicine and Cancer Biology
    Department of Internal Medicine
    Vanderbilt University School of Medicine
    Nashville, Tennessee

    Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, CTI BioPharma Corp, Geron, Karyopharm Therapeutics, Novartis, Ryvu Therapeutics, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements and Ownership Interest: Karyopharm Therapeutics, Ryvu Therapeutics; Contracted Research: ALX Oncology, Incyte Corporation, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Sierra Oncology, TG Therapeutics Inc.

    Eunice S Wang, MD
    Chief, Leukemia Service
    Professor of Oncology
    Roswell Park Comprehensive Cancer Center
    Buffalo, New York

    Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, and Novartis.

    Release date: June 2022
    Expiration date: June 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):